Search Results 731-740 of 16981 for monoclonal antibody

1. Testing the Addition of an Anti-cancer Drug, ASTX727, to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer - Mayo Clinic

   Patients who have received prior PD-1/PD-L1 monoclonal antibodies in any disease setting are eligible. ... antibody agent, ASTX727 is a hypomethylating ...

2. A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors - Mayo Clinic

   A Phase 1/2, First-in-Human, Open Label, Dose Escalation Study Of A CSP Targeting Functional Antibody in Solid Tumors. Print details. Share; Facebook · Twitter.

3. A Study To Evaluate The Efficacy, Safety, Pharmacokinetics, And Pharmacodynamics Of Satralizumab In Patients With Anti-N-Methyl-D-Aspartic Acid Receptor (NMDAR) Or Anti-Leucine-Rich Glioma-Inactivated 1 (LGI1) Encephalitis (Cielo) - Mayo Clinic

   * Any previous treatment with anti-CD19 antibody, complement inhibitors, neonatal Fc receptor antagonists, anti-B-lymphocyte stimulator monoclonal antibody * ...

4. Germ Cell Tumors Clinical Trials - Mayo Clinic Research

   Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ...

5. Model Clarifies Immunotherapy for Multiple Myeloma - Mayo Clinic News Network

   The authors report that the mouse model helped evaluate different ways to combine standard chemotherapies with the antibody drugs. They evaluated toxicity ...

6. A Study of Using Lorvotuzumab Mertansine in Treating Younger Patients with Relapsed or Refractory Wilms Tumor, Rhabdomyosarcoma, Neuroblastoma, Pleuropulmonary Blastoma, Malignant Peripheral Nerve Sheath Tumor, or Synovial Sarcoma - Mayo Clinic

   Antibody-drug conjugates, such as lorvotuzumab mertansine, are created by ... monoclonal antibody; ≥ 2 weeks must have elapsed since local palliative ...

7. Immune Predictors of Response to Pembrolizumab Therapy in Stage IV Melanoma Patients - Mayo Clinic

   Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., ≤ Grade 1 or at baseline) from ...

8. ACTIV-5 / Big Effect Trial (BET-B) for the Treatment of COVID-19 - Mayo Clinic

   Received monoclonal antibodies targeting cytokines (e.g., tumor necrosis factor (TNF) inhibitors, anti-IL-1 [e.g., anakinra, canakinumab], anti-IL-6 [e.g. ...

9. Patients with blood cancer precursor at risk of developing cancer even after 30 years - Mayo Clinic News Network

   These are the findings of a study by Mayo Clinic researchers published in the Wednesday, Jan. 17, issue of the New England Journal of Medicine. Monoclonal ...

10. Myeloma, Amyloidosis, Dysproteinemia Group - Overview - Mayo Clinic

    Monoclonal gammopathy-associated conditions including C1-esterase inhibitor deficiency, cryoglobulinemia, osteosclerotic myeloma, peripheral neuropathy ...